多发性骨髓瘤的多学科协作诊疗模式

刘澎; 李晶; 徐天虹; 魏征; 柯杨; 承璐雅

doi:10.13201/j.issn.1004-2806.2021.07.002

多发性骨髓瘤的多学科协作诊疗模式

- 复旦大学附属中山医院血液科(上海, 200032)

详细信息

通讯作者: 刘澎,E-mail:liu.peng@zs-hospital.sh.cn,教授,主任医师,博士生导师,复旦大学附属中山医院血液科主任。复旦大学校聘关键岗位引进人才。上海市卫生系统优秀学科带头人。中华医学会血液分会委员,中国生物医学工程学会干细胞工程技术分会副主任委员,上海市医学会分会副主任委员,上海市肿瘤防治联盟淋巴瘤专委会主任委员,上海市抗癌协会血液肿瘤专委会副主任委员。担任国家自然科学基金评审专家。主持国家自然科学基金(3项)

中图分类号: R733.3

收稿日期: 2021-05-11

Multidisciplinary team collaboration in diagnosis and treatment of multiple myeloma

More Information

Corresponding author: LIU Peng, E-mail: liu.peng@zs-hospital.sh.cn

Received Date: 11 May 2021

摘要

- 多发性骨髓瘤 /
- 多学科协作 /
- 诊断 /
- 治疗
- multiple myeloma /
- multidisciplinary team collaboration /
- diagnosis /
- treatment

HTML全文

参考文献(15)

[1]	Liu W,Liu J,Song Y,et al.Mortality of lymphoma and myeloma in China,2004-2017:an observational study[J].J Hematol Oncol,2019,12(1):22.
[2]	Lu J,Lu J,Chen W,et al.Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma:results of a multicenter analysis[J].Blood Cancer J,2014,4:e239.
[3]	Excellence NIOC.National Institute of Clinical Excellence(2003) Guidance on Cancer Services-Improving Outcomes in Haematological Cancers[OL].https://www.nice.org.uk/guidance/NG47/chapter/Recommendations#multidisciplinary-teams,2003.
[4]	Herget GW,Kalberer F,Ihorst G,et al.Interdisciplinary approach to multiple myeloma-time to diagnosis and warning signs[J].Leuk Lymphoma,2021,62(4):891-898.
[5]	Kyle RA,Gertz MA,Witzig TE,et al.Review of 1027 patients with newly diagnosed multiple myeloma[J].Mayo Clin Proc,2003,78(1):21-33.
[6]	Hillengass J,Usmani S,Rajkumar SV,et al.International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders[J].Lancet Oncol,2019,20(6):e302-e312.
[7]	Singh J,Fairbairn KJ,Williams C,et al.Expert radiological review of skeletal surveys identifies additional abnormalities in 23% of cases:further evidence for the value of myeloma multi-disciplinary teams in the accurate staging and treatment of myeloma patients[J].Br J Haematol,2007,137(2):172-173.
[8]	Gay F,Engelhardt M,Terpos E,et al.From transplant to novel cellular therapies in multiple myeloma:European Myeloma Network guidelines and future perspectives[J].Haematologica,2018,103(2):197-211.
[9]	Gonsalves WI,Buadi FK,Ailawadhi S,et al.Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma:a Mayo Stratification of Myeloma and Risk-Adapted Therapy(mSMART)consensus statement[J].Bone Marrow Transplant,2019,54(3):353-367.
[10]	Bridoux F,Carron PL,Pegourie B,et al.Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy:A Randomized Clinical Trial[J].JAMA,2017,318(21):2099-2110.
[11]	Terpos E,Morgan G,Dimopoulos MA,et al.International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease[J].J Clin Oncol,2013,31(18):2347-2357.
[12]	Mohty B,El-Cheikh J,Yakoub-Agha I,et al.Peripheral neuropathy and new treatments for multiple myeloma:background and practical recommendations[J].Haematologica,2010,95(2):311-319.
[13]	Palumbo A,Rajkumar SV,San Miguel JF,et al.International Myeloma Working Group consensus statement for the management,treatment,and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J].J Clin Oncol,2014,32(6):587-600.
[14]	Richardson PG,Delforge M,Beksac M,et al.Management of treatment-emergent peripheral neuropathy in multiple myeloma[J].Leukemia,2012,26(4):595-608.
[15]	Plummer C,Driessen C,Szabo Z,et al.Management of cardiovascular risk in patients with multiple myeloma[J].Blood Cancer J,2019,9(3):26.